This mitochondrial advantage supports faster proliferation, increased cytokine production, and sustained ATP levels, essential for rapid response to reinfection.[30] In PD‐1 blockade therapy, increased mitochondrial mass and ROS production in tumor‐reactive CD8+ T cells within draining lymph nodes enhance T cell expansion and antitumor activity when combined with activation of mTOR, AMPK, or PGC‐1α. Here, CD8A is linked to neoplasm.